PTCT insider trade: 3,375 shares sold, 3,375-share option acquired

Rhea-AI Filing Summary

PTC Therapeutics insider Mark Elliott Boulding, Executive Vice President and Chief Legal Officer, reported transactions on 10/07/2025 under a written Rule 10b5-1 plan adopted on 12/05/2024. He acquired a stock option for 3,375 shares with an exercise price of $38.10 and an expiration date of 01/06/2032. On the same date he sold a total of 3,375 common shares in three weighted-average-price tranches for aggregate proceeds at weighted prices of $62.89, $63.80, and $64.97 (ranges disclosed per tranche). After these transactions he beneficially owned 103,901 shares.

Positive

• Transactions executed under a written Rule 10b5-1 plan adopted on 12/05/2024
• Acquisition of a long-dated stock option for 3,375 shares at an exercise price of $38.10 (expiring 01/06/2032)
• Post-transaction beneficial ownership remains substantial at 103,901 shares

Negative

• Officer sold 3,375 shares on 10/07/2025, which reduces direct shareholdings
• Sales executed at prices notably above the option exercise price (weighted averages of $62.89, $63.80, and $64.97) which may crystallize tax or diversification outcomes

Insights

Corporate Governance Expert

TL;DR: An officer used a 10b5-1 plan to sell shares while taking new option-based compensation.

Boulding reported concurrent sales of 3,375 common shares and the acquisition of a 3,375-share stock option on 10/07/2025. The option has a $38.10 exercise price and expires on 01/06/2032, and vests per the original grant schedule from 01/07/2022.

The sales were made under a written Rule 10b5-1 plan established on 12/05/2024, which provides an affirmative defense for preplanned trades; monitor any future amendments or additional filings that change beneficial ownership or option holdings within the next 12 months.

Insider Trading Compliance Expert

TL;DR: Transactions appear executed under a documented compliance plan with detailed price ranges disclosed.

The filing discloses sales executed in multiple tranches at weighted average prices: $62.89, $63.80, and $64.97, with underlying trade price ranges provided for each tranche. The reporting person offers to provide split trade details upon request by regulators or the issuer.

Because the plan date (12/05/2024) precedes the transaction date, these trades align with the mechanics of a 10b5-1 program; compliance observers would watch for additional Form 4s showing further plan-driven activity in the next quarter.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boulding Mark Elliott

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EXEC. VP AND CLO

3. Date of Earliest Transaction (Month/Day/Year)
10/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/07/2025		M(1)		3,375	A	$38.1	107,276	D
Common Stock	10/07/2025		S(1)		1,757	D	$62.89(2)	105,519	D
Common Stock	10/07/2025		S(1)		1,306	D	$63.8(3)	104,213	D
Common Stock	10/07/2025		S(1)		312	D	$64.97(4)	103,901	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$38.1	10/07/2025		M(1)			3,375	(5)	01/06/2032	Common Stock	3,375	$0	3,376	D

Explanation of Responses:

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $62.36 to $63.28 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

3. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $63.36 to $64.25 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

4. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.56 to $65.01 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

5. This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023.

	/s/ Avraham S. Adler, Attorney-in-Fact	10/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Mark Elliott Boulding report on Form 4 for PTCT?

He reported sales of 3,375 common shares and the acquisition of a 3,375-share stock option on 10/07/2025 under a 10b5-1 plan.

Were the transactions executed under a 10b5-1 trading plan (PTCT)?

Yes, the filing states the trades were effected pursuant to a written Rule 10b5-1 plan adopted on 12/05/2024.

What prices were the PTCT shares sold at in the Form 4?

Sales were reported as weighted-average prices of $62.89, $63.80, and $64.97, with underlying trade ranges disclosed per tranche.

How many PTCT shares does the reporting person own after the transactions?

The reporting person beneficially owned 103,901 common shares following the reported transactions.

What are the terms of the option acquired in the Form 4 (PTCT)?

The option covers 3,375 shares, has an exercise price of $38.10, vests per the original grant, and expires on 01/06/2032.